The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Molecular basis for sunitinib efficacy and future clinical development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Self-citationEndothelial Progenitor Cells: Characterization and Role in Vascular Biology
Urbich, C., & Dimmeler, S. (2004) · Circulation Research · doi:10.1161/01.res.0000137877.89448.78 · Cited by 2,369
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Rehman, J., Li, J., Orschell, C. M., & March, K. L. (2003) · Circulation · doi:10.1161/01.cir.0000058702.69484.a0 · Cited by 1,686
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Self-citationSU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 636
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 633
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 521
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Hida, K., Hida, Y., Amin, D. N., Flint, A. F., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470
Raut, C. P., Posner, M., Desai, J., Morgan, J. A., George, S., Zahrieh, D., Fletcher, C. D. M., Demetri, G. D., & Bertagnolli, M. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3439 · Cited by 448
Self-citationDebiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., Dimitrijevic, S., Sciot, R., Stul, M., Vranck, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.025 · Cited by 444
Macrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
Humar, R., Kiefer, F. N., Berns, H., Resink, T. J., & Battegay, E. J. (2002) · The FASEB Journal · doi:10.1096/fj.01-0658com · Cited by 381
Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis
Cao, Y. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1693 · Cited by 307
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question
Whelan, T., & Levine, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.955 · Cited by 304
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
Self-citationOncogenic protein tyrosine kinases: Kit as a human oncogenic tyrosine kinase
Kitamura, Y., & Hirotab, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4273-y · Cited by 260
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Placental growth factor is a survival factor for tumor endothelial cells and macrophages.
Adini, A., Kornaga, T., Firoozbakht, F., & Benjamin, L. E. (2002) · PubMed · Cited by 212
Ichihara, M. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00456-7 · Cited by 197
New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
(2000) · Advances in Cancer Research · doi:10.1016/s0065-230x(00)79001-4 · Cited by 193
Osusky, K. L., Hallahan, D. E., Fu, A., Ye, F., Shyr, Y., & Geng, L. (2004) · Angiogenesis · doi:10.1007/s10456-004-3149-y · Cited by 153
The involvement of endothelial progenitor cells in tumor angiogenesis
Ribatti, D. (2004) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2004.tb00319.x · Cited by 149
Sunitinib malate for the treatment of solid tumours: a review of current clinical data
Motzer, R. J., Hoosen, S., Bello, C. L., & Christensen, J. G. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.553 · Cited by 119
The Role of CSF-1 in Normal Physiology of Mammary Gland and Breast Cancer: An Update
Sapi, E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900101 · Cited by 104
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
Huang, J., Soffer, S. Z., Kim, E. S., McCrudden, K. W., Huang, J. T., New, T. N., Manley, C. A., Middlesworth, W., O’Toole, K., Yamashiro, D. J., et al. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.36.2.1 · Cited by 101
Socinski, M. A., Novello, S., Sanchez, J. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7001 · Cited by 101
Socinski, M. A., Weissman, C., Hart, L. L., Beck, J. T., Choksi, J. K., Hanson, J. P., Prager, D., Monberg, M., Ye, Z., & Obasaju, C. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.7016 · Cited by 83
Response of Intracranial Metastases to Erlotinib Therapy
Fekrazad, M. H., Ravindranathan, M., & Jones, D. V. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3751 · Cited by 77
Biology of Gastrointestinal Stromal Tumors: KIT Mutations and Beyond
Duensing, A. U., Heinrich, M. C., Fletcher, C. D. �., & Fletcher, J. A. (2004) · Cancer Investigation · doi:10.1081/cnv-120027585 · Cited by 76
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells.
Grimshaw, M. J., Naylor, S., & Balkwill, F. R. (2002) · PubMed · Cited by 74
Faivre, S. J., Raymond, É., Douillard, J., Boucher, É., Lim, H. Y., Js, K., Lanzalone, S., Lechuga, M. J., Sherman, L. J., & Cheng, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3546 · Cited by 71
Self-citationOncogenic protein tyrosine kinases
Naoe, T., & Kiyoi, H. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4274-x · Cited by 61
Morimoto, A. M., Tan, N., West, K. A., McArthur, G. A., Toner, G. C., Manning, W. C., Smolich, B. D., & Cherrington, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207268 · Cited by 46
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Development and plasticity of meningeal lymphatic vessels
Antila, S., Karaman, S., Nurmi, H., Airavaara, M., Voutilainen, M. H., Mathivet, T., Chilov, D., Li, Z., Koppinen, T., Park, J.-H., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170391 · Cited by 466
Metadata
- Authors
- Faivre, S., Demetri, G., Sargent, W., & Raymond, E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-09
- Volume
- 6
- Issue
- 9
- Pages
- 734-745
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2039155298
- Cited by
- 721
- References
- 52
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.